Hypera, a pharmaceutical company, completed the acquisition of selected OTC assets of Takeda Pharmaceutical, a pharmaceutical company, for $825m. The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business Unit. The products, while addressing key patient needs in these countries, are outside of the business areas Takeda has designated as core to its global long-term growth. “This announcement marks the latest step in Takeda’s strategy of streamlining and optimizing our portfolio while accelerating our deleveraging. By continuing to focus on our key business areas and pipeline of innovative medicines, we will strengthen our position as a R&D driven global biopharmaceutical leader and deliver enhanced value for patients and Takeda shareholders,” Costa Saroukos, Takeda Chief Financial Officer.